ABT recently announced its 2012 financial results. The Company had its commercial breakthrough in 2012 and posted revenues of NOK 20.3 million for the year. ABT’s revenues the year before were NOK 0.5 million.
Contracts with two US based customers are the main reason for the commercial success. Aqua Bio Technology’s lead ingredient Aquabeautine XL™ is now included in new skincare products being widely marketed.
Aqua Bio Technology’s EBITDA for 2012 ended at NOK 8.0 million, compared to NOK -8.1 million in 2011. The company’s net result for the year was NOK 0.9 million, against NOK -13.5 the previous year.
For the fourth quarter alone, ABT posted revenues of NOK 3.4 million and an EBITDA of NOK 0.2 million. Net result for the fourth quarter was NOK -2.7 million.
The contracts secure ABT total revenues of more than NOK 120 million in the period 2012-2017, in the form of exclusivity and minimum royalty payments for Aquabeautine XL™. Product sales are expected to provide additional revenues.
ArcticZymes AS, a subsidiary company of Biotec Pharmacon ASA, has received a grant of NOK 5 million from the The Research Council of Norway, for a project titled “Functionalization of enzymes from marine bioprospecting”. The total project budget is NOK approx. 10 million over 3 years.
The project is a user driven innovation project which aims to accelerate the commercialization of new functionalized enzyme solutions in the Bioprospecting program under The Research Council’s Biotek2021 initiative.
ArcticZymes’ enzyme portfolio is expanding quickly, primarily due to the progress of strategic partnerships with MabCent, MARZymes and others, and results from the ongoing InnoZymes project which received funding from The Research Council’s Functional Genomics in Norway (FUGE) program in April 2011
A new nasal spray from a marine microbe will help clear chronic sinusitis, which causes nasal congestion, difficulty in breathing, pain and swelling around your eyes and cheeks. A team of scientists and surgeons from Newcastle University are developing the spray with an enzyme isolated from a marine bug Bacillus licheniformis, found on the surface of seaweed.
Lab experiments showed that the enzyme, called NucB, dispersed 58 per cent of biofilms in chronic sinusitis formed by the marine bug. The biofilm acts as a slimy barrier to protect bugs from sprays or antibiotics, the journal Public Library of Science ONE reports.
The marine ecosystem is still an untapped reservoir of biologically active compounds, which have considerable potential to supply food ingredients towards development of new functional foods. With the goal of increasing the availability and chemical diversity of functional marine ingredients, much research has been developed using biotechnological tools to discover and produce new compounds.
This review summarizes the advances in biotechnological tools for production of functional ingredients, including enzymes, for the food industry. Tools involving biotechnological processes (bioreactors, fermentations, bioprocessing) and those involving genetic research designated as molecular biotechnology are discussed highlighting how they can be used in the controlled manipulation and utilization of marine organisms as sources of food ingredients, as well as discussing the most relevant shortcomings towards applications in new functional foods.
Norwegian firm Aqua Bio Technology has reported a fall in revenue in the second quarter of 2012. The company posted a significant sales increase in the first quarter of the year when two major contracts boosted income to NOK11.9m. However, second quarter income was just NOK0.1m, compared with NOK0.4m in the same period of 2011.
The company, which is responsible for Aquabeautine XL, an anti-ageing skin care ingredient derived from the hatching fluid of salmon, reported sales of NOK12.1m in the first half of the year, a considerable increase compared with sales of NOK0.4m in the prior year period.
The company expects the launch of three new products in September will boost income in the second half of 2012. The products will be launched ahead of schedule – the result of accelerated product development in the second quarter. And based on the current order backlog, ABT forecasts significant sales growth in the second half of 2012 and in coming years.
The 6th BIOPROSP Conference
A biennial International Conference on Marine Bioprospecting from cold marine environment.
To be held in the world’s northernmost University City in February 20th – 22nd in Tromsø, Norway.
BIOPROSP_13 will focus on the challenges and possibilities related to industrial applications of marine bioactive compounds
Biotech and pharmaceutical industry, scientists, medicine, cosmetics, public support system, decision-makers and others interested in marine bioprospecting.
In a pioneering collaboration the leading Scottish biotechnology company Aquapharm and German industrial biotechnology firm c-LEcta are set to fast-track the discovery and commercialisation of a new wave of bio-catalysts.
c-LEcta is skilled in the identification and engineering of enzymes and strains for optimized bio-catalytic industry processes, whilst Aquapharm has proven expertise in harnessing the commercial potential of its unique collection of marine bacteria and fungi.
Together the partners will strengthen and expand their ability to provide innovative solutions across many market areas including production of natural, sustainably produced food, beverage and personal care ingredients.
Scientists are developing a unique seaweed toothpaste that can protect teeth and gums from bacteria in the mouth, which cause tooth decay.
Scientists from the Newcastle University discovered the new seaweed’s medicinal qualities while analysing an enzyme from the marine bacterium, Bacillus licheniformis, which is found on the surface of the seaweed.
The enzyme is usually used for cleaning the hulls of ships but now scientists claim that the enzyme can be used for cleaning the tooth because of its medicinal properties.
“When I initially began researching how to break down these layers of bacteria, I was interested in how we could keep the hulls of ships clear but we soon realized that the mechanism we had discovered had much wider uses. If we can contain it within toothpaste we would be creating a product which could prevent tooth decay,” said Dr Nicholas Jakubovics, researcher at the
Growing International Interest In Oceanology To Benefit The Global Marine Biotechnology Market, According To New Report By Global Industry Analysts, Inc.Posted On: April 24, 2012
With growing environmental pollution throwing the spotlight on sustainable industrial development, there exists huge demand for suitable, scalable, economically, socially and environmentally sustainable feedstock options for the manufacturing industry. With sustainable feedstock production and delivery ballooning into a massive industry worldwide, the world’s oceans have emerged into the next frontier for investigative, biological resource development and management R&D projects.
For instance, marine-derived cosmetic ingredients, marine-derived molecules including enzymes, biopolymers and biomaterials, marine-derived pharmaceuticals, among others, are now becoming the mainstay of most R&D projects worldwide. The marine biotechnology sector is also attracting increased venture capital funds as is mirrored by the mushrooming of potential laden start-up firms focused on developing novel compounds from marine organisms.
As stated by the new market research report on Marine Biotechnology, Bioactive Substances represents one of the fastest growing market sectors trailing a projected CAGR of approximately 4.7% respectively.
The research report titled “Marine Biotechnology: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the marine biotechnology markets, impact of recession on the markets, current market trends, key growth drivers, recent product introductions, recent industry activity, and profiles of major/niche global as well as regional market participants.
Aqua Bio Technology ASA (Oslo Axess: ABT) today announced a partnership with Amway, one of the world’s largest direct sellers, for the use of ABT’s lead marine-derived ingredient Aquabeautine XL® in ARTISTRY® skincare products. ABT expects the agreement to provide revenues of at least NOK 8 million over the next 30 months, with a significant upside potential.
“The agreement with Amway is our most important commercial milestone to date. It confirms the potential of Aquabeautine XL® as a key component in the next generation of skincare products. Furthermore, our relationship with Amway will serve as an important reference as we roll out our new marketing strategy,” said ABT’s CEO Arvid Lindberg.
Michigan, US-based Amway is a worldwide leader in direct selling, with more than three million Independent Business Owners (IBOs) in more than 80 countries and territories around the world. Its ARTISTRY® is among the world’s top five, largest-selling, premium skincare brands.